论文部分内容阅读
2011年6月,欧盟委员会批准了Novartis公司的雷尼珠单抗(ranibizumab/Lucentis)一新适应证,即以每月1次眼内注射方案治疗视网膜静脉闭塞所致黄斑水肿患者,以改善他们的视敏度及视敏度相关生活质量。雷尼珠单抗为抗血管内皮生长因子抗体片段,具有中和血管内皮生长因子的作用。
In June 2011, the European Commission approved Novartis’s new indication for ranibizumab / Lucentis to treat patients with macular edema caused by retinal vein occlusion with an intraocular injection once per month in order to improve them Visual acuity and visual acuity-related quality of life. Racinizumab is an anti-vascular endothelial growth factor antibody fragment that has the effect of neutralizing vascular endothelial growth factor.